IRIDEX Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended January 1, 2022; comparison is fiscal year ended January 2, 2021. This is an annual report, not a standalone fourth-quarter filing. FY2021 and FY2020 comprised 52 and 53 weeks, respectively.
Business context
Iridex develops and sells ophthalmic laser systems, delivery devices and consumables used to treat glaucoma and retinal diseases. Products include Cyclo G6, IQ laser systems, OcuLight and PASCAL. Consumables, repairs and service contracts contribute recurring revenue. Sales are made directly in the United States and Germany and primarily through distributors elsewhere.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $53.9 million | $36.3 million |
| Gross profit / margin | $22.8 million / 42.4% | $15.6 million / 42.8% |
| Operating loss | $7.5 million | $6.6 million |
| Net loss | $5.2 million | $6.3 million |
| Net loss per diluted share | $0.34 | $0.46 |
| Operating cash flow | $8.2 million provided | $3.2 million used |
- Revenue rose 48.3%. Retina revenue increased 72.0% to $31.1 million; Cyclo G6 revenue increased 23.7% to $14.0 million. The company attributed growth to recovery from pandemic-disrupted activity and inclusion of PASCAL sales.
- Operating expenses rose to $30.4 million from $22.1 million, including higher R&D spending and costs associated with growth and the PASCAL acquisition. Gross margin edged down 0.4 percentage points, reflecting geographic and product mix.
- Other income was $2.3 million, including a $2.5 million gain from forgiveness of the PPP loan. The loan was fully forgiven in June 2021.
- At year-end, cash and cash equivalents were $23.9 million, working capital was $29.7 million, and total liabilities were $25.4 million. The company reported no outstanding borrowings under its revolving credit facility; PPP debt was extinguished.
- Operating cash flow included a $12.1 million increase in deferred revenue, largely associated with Topcon distribution-rights payments. Investing cash flow used $5.6 million, principally for the PASCAL acquisition; financing provided $9.5 million, primarily from the $10 million Topcon-related stock issuance.
Material changes and notable items
- In March 2021, Iridex acquired substantially all of Topcon Medical Laser Systems’ PASCAL business for approximately $5.3 million and granted Topcon exclusive distribution rights for certain international regions. Topcon also purchased 1,618,122 Iridex shares for $10 million, or 10.2% of the company’s voting interest.
- The distribution-rights arrangement has an estimated fair value of approximately $14.8 million and is recognized as revenue over a 10-year period as regional approvals take effect. Iridex recorded $0.6 million of related revenue in FY2021. Certain approvals and regional arrangements remain relevant to the arrangement’s payment and recognition.
- Topcon accounted for 21% of FY2021 revenue and was a related party. Year-end receivables from Topcon were $3.1 million; payables were $0.6 million. Japan represented 13.5% of FY2021 revenue; international sales overall were 52.6%.
- Inventory was $7.6 million, up from $5.7 million. The auditor identified inventory valuation—particularly estimates for excess or obsolete inventory—as a critical audit matter. The audit opinion on the financial statements was unqualified.
Outlook, risks and contingencies
- Management said demand and its outlook had improved but anticipated that COVID-19 uncertainty and healthcare resource pressures could continue to defer customers’ capital spending. It expected operating losses and negative operating cash flows through December 31, 2022, while stating that existing cash was expected to cover anticipated needs for the next 12 months. No specific revenue or earnings guidance was provided.
- Key risks include ongoing pandemic effects, supply-chain constraints and dependence on sole- or limited-source suppliers, manufacturing and product-quality issues, competition, reliance on international distributors and Topcon, reimbursement changes, and regulatory compliance. The company also cited exposure to foreign exchange, trade and geopolitical uncertainty.
- A voluntary 2018 recall of the TruFocus LIO Premiere remained pending FDA termination; the company submitted a follow-up termination request in September 2021. The filing reports no material legal proceedings.
- Purchase commitments were approximately $18.0 million. The company reported no off-balance-sheet arrangements. Its Mountain View facility lease was extended through August 2024.
Investor verification points
- Track whether Topcon achieves distribution sales baselines, regional approvals, and expected commercialization; review the related deferred revenue and customer receivable balances.
- Assess the quality and sustainability of operating cash flow, including its dependence on deferred revenue and collection timing, against continued operating losses.
- Monitor inventory growth, reserves and demand forecasts, given the auditor’s critical audit matter and reliance on management estimates.
- Check progress toward reducing losses and negative cash flows, and compare actual liquidity needs with management’s 12-month sufficiency assessment.
- Follow the FDA status of the LIO recall and EU medical-device certification requirements, as well as supply availability and customer demand amid pandemic-related uncertainty.